Thrasos Therapeutics, a US-based biotherapeutics company developing treatments for kidney disease, has closed a $21m series D round co-led by SR One, the corporate venturing arm of pharmaceutical company GlaxoSmithKline.
BDC Capital, a subsidiary of the Business Development Bank of Canada, co-led the round which will support a Phase 2 clinical trial of a treatment for the prevention of acute kidney injury.
In 2012, Thrasos secured a $35m series C round led by SR One and featuring SW Company, Advanced…
